Pfizer Inc. and BioNTech SE disclosed “positive” data from an early trial of their BNT162b2 mRNA-based vaccine candidate against SARS-CoV2 and confirmed that they were on track to seek regulatory review as early as October.The news drove BioNTech (BNTX) shares up 10% on Friday, while Pfizer rose less than 1% at the close of day.Pfizer (PFE) and BioNTech shared additional Phase 1 safety and immunogenicity data from their ongoing US study of the BNT162 mRNA-based vaccine program against Covid-19.The newly released data shows key safety and immunogenicity data from the US Phase 1 trial for the BNT162b2 vaccine candidate, which …read more
Source:: Yahoo Finance
